In rats, it has been reported that rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, reacts with the aldehyde group of allysine in elastin to give a condensation covalent adduct, thereby preventing the formation of cross-linkages in the elastin and causing degradation of the elastic fibers in aortas in vivo. Acid, organic solvent, and proteolytic enzyme treatments of human aortic homogenate after incubation with 
In 2004, rofecoxib (Vioxx; Merck & Co. Inc., Whitehouse Station, NJ), a potent and highly selective cyclooxygenase-2 (COX-2) inhibitor, was withdrawn from the worldwide market based on the results of some clinical studies indicating its association with increased risk of cardiovascular (CV) events, such as heart attack and stroke (Merck, Merck announces voluntary worldwide withdrawal of Vioxx. (http:// www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf) . In the last few years, it has been reported that other selective e.g., etoricoxib, valdecoxib (and its prodrug, parecoxib) , and even nonselective nonsteroidal anti-inflammatory drugs, e.g., naproxen, may also have a potential for increased CV risk (National Institutes of Health, Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. http: //www. nih.gov/news/pr/dec2004/od-20.htm) (Aldington et al., 2005; Nussmeier et al., 2005) . However, rofecoxib has a distinctly higher potential for CV risk in comparison with these drugs (Fredy et al., 2005; Graham et al., 2005) . Although some hypotheses regarding the mechanism have been proposed so far, such as prostacyclin (PGI 2 )/thromboxane A 2 (TxA 2 ) imbalance in arteries (McAdam et al., 1999) , most of these hypotheses have not been verified yet.
In our previous study using rat aortas (Oitate et al., 2007) , it was suggested that rofecoxib itself reacts with the aldehyde group of allysine (␣-aminoadipic-␦-semialdehyde) in elastin to give a condensation covalent adduct (Fig. 1B ). This was also strongly supported by an in vitro reaction using benzaldehyde, a model compound of allysine, in which rofecoxib reacted with the aldehyde group of benzaldehyde in a kind of condensation reaction under a physiological pH condition. Similar to collagen, elastin is a key extracellular matrix protein which provides CV tissues, e.g., arteries and heart valves, with tensile strength and elasticity (Vrhovski and Weiss, 1998) . The elastic property is due to the existence of covalent cross-linkages, such as desmosine and isodesmosine, and allysine is the most important precursor of physiologically essential cross-linkage formation in elastin and collagen and is formed from the lysine residue by lysyl oxidase (LOX) (Fig. 1A) . It has been reported that the prevention of these cross-linkages in elastin or collagen causes serious lesions in the connective tissues in animals and humans (Herd and Orbison, 1966; Andrews et al., 1975; Hashimoto et al., 1981; Junker et al., 1982; Light et al., 1986; Yoshikawa et al., 2001) . In fact, multiple oral administration of rofecoxib to rats caused a marked degradation of the elastic fibers in the aorta in vivo, conceivably by covalently binding to allysine aldehyde and by the inhibition of the normal cross-linking process of elastin (Oitate et al., 2007) . In the present study, to investigate whether the above observations seen in rats also occur in clinical situations, that is, whether rofecoxib can bind with allysine aldehyde in human elastin, we conducted in vitro binding studies using a human aorta sample. In addition, the reactivity of other COX-2 inhibitors, celecoxib (Celebrex; Pfizer, New York, NY), valdecoxib (Bextra; Pfizer), etoricoxib (Arcoxia; Merck & Co. Inc.), and CS-706 [2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole], a novel COX-2 inhibitor, with allysine aldehyde was estimated using benzaldehyde, and their inhibitory potencies in the cross-linking process of human elastin were evaluated.
Materials and Methods

Chemicals and Reagents. [
14 C]Rofecoxib (17 mCi/mmol) and [ 14 C]celecoxib (13 mCi/mmol) were synthesized at GE Healthcare Biosciences (Little Chalfont, Buckinghamshire, UK; radiochemical purities; Ͼ98%), and nonradiolabeled rofecoxib, celecoxib, valdecoxib, etoricoxib, and CS-706 were synthesized at Daiichi Sankyo Co., Ltd. (Tokyo, Japan) (Fig. 2) . ␤-Aminopropionitrile (BAPN), D-penicillamine, hydralazine, and benzaldehyde were purchased from Sigma-Aldrich Inc. (St. Louis, MO). All other reagents and solvents used were commercially available and were of extra pure, guaranteed or high-performance liquid chromatography (HPLC) and liquid chromatography/mass spectrometry (LC/MS) grade.
Animals and Sample Collection. Male Sprague-Dawley rats (6 weeks of age) were obtained from Charles River Japan, Inc. (Yokohama, Japan) and were used after 1 week of acclimatization. The rats were housed in a temperature-controlled room with a 12-h light/dark cycle and were allowed free access to water and a diet (FR-2; Funabashi Farm Co., Ltd., Chiba, Japan) throughout the study. The thoracic aortas were collected from the rats weighing 210 to 230 g after being euthanized by exsanguination under diethyl ether anesthesia (n ϭ 10).
Procurement of Human Aorta Sample. A human abdominal aorta (Caucasian, female, 69 years old) was obtained from the Human Animal Bridging Research Organization in Chiba, Japan. The sample was legally procured from the National Disease Researcher Interchange in Philadelphia, PA, with permission to use the aorta for research purposes only, based on the international partnership between the National Disease Researcher Interchange and Human Animal Bridging Research Organization.
Cell Culture. Human aortic endothelial cells (HAOEC) were obtained from Cell Applications, Inc. (San Diego, CA). The cells were cultured in endothelial cell medium (HAOEC Total Kit; Cell Applications, Inc.) according to the supplier's instructions. For the uptake and efflux experiments, HAOEC were seeded at 9.0 ϫ 10 4 cells/cm 2 in 24-well dishes (type I collagen-coated plate; Asahi Techno Glass, Tokyo, Japan) and used at 90% confluence.
Acid, Organic Solvent, and Proteolytic Enzyme Treatments of Human Aorta. After the removal of the adhering tissues, the human aortic sample was weighed and homogenized [5% (w/v)] in isotonic saline using a motor-driven homogenizer. The homogenate in final volume of 10 ml was incubated with [ 14 C]rofecoxib (100 M) at 37°C for 2 h (n ϭ 1). After the incubation, to the homogenates 30 ml of 0.9 M trichloroacetic acid (TCA) was added to precipitate the proteins. Then, the mixture was centrifuged at 2000g at room temperature for 10 min. The supernatant was discarded, and the precipitate was washed by resuspension and centrifugation successively with 0.6 M TCA, 80% (v/v) methanol, and 100% methanol until only background radioactivity was measured in each wash. According to a previous report (Oitate et al., 2006) , the resulting precipitate was enzymatically treated successively with collagenase (25,000 units, from Clostridium histolyticum; Wako Pure Chemical Industries, Ltd., Osaka, Japan) in 0.1 M Tris-HCl buffer, pH 8.0, at 37°C for 16 h, elastase (4000 units, from porcine pancreas; Wako Pure Chemical Industries, Ltd.) in 0.1 M Tris-HCl buffer, pH 8.5, at 37°C for 16 h, and pronase (10,000 units, from Streptomyces griseus; Merck, Darmstadt, Germany) in 0.1 M sodium phosphate buffer, pH 7.5, at 37°C for 16 h, and then the radioactivity recovered in each proteolytic fraction was measured.
In Vitro Covalent Binding of [ 14 C]Rofecoxib to Human Aorta Homogenate and Effect of Protein Modifiers. Homogenate samples of the human aorta were prepared as described above. According to a previous report (Oitate et al., 2007) , the homogenates were each pretreated with 10 mM of protein modifiers BAPN, D-penicillamine, or hydralazine in potassium phosphate buffer (100 mM, pH 7.4) at 37°C for 0.5 h, and then incubated with [ 14 C]rofecoxib (100 M) at 37°C for 2 h (n ϭ 3). As a control, the homogenate was pretreated with buffer alone. For evaluating the nonspecific binding, the same treatments were performed at 4°C. After the incubation, 3-fold volume of 0.9 M TCA was added to the incubation mixture to precipitate the proteins. Then, the mixture was centrifuged at 4°C for 10 min. The supernatant was removed for radiodetection HPLC analysis, and the precipitate was washed by resuspension and centrifugation successively with 0.6 M TCA, 80% (v/v) methanol, and 100% methanol until only background radioactivity was measured in the centrifuged supernatants of each washing step. The resulting precipitates were air-dried and subjected to radioactivity measurement. The net amount of covalent binding was calculated by subtracting the nonspecific binding from the total. The LOX activity in the samples was measured as previously reported (Oitate et al., 2007) .
In Vitro Covalent Binding of [ 14 C]Rofecoxib to Rat and Human Aorta Homogenates and Effect of Several COX-2 Inhibitors. After the removal of the adhering tissues, the rat and human aortic samples were weighed and homogenized [5% (w/v)] in isotonic saline using a motor-driven homogenizer. The homogenates were incubated with [
14 C]rofecoxib (50 M) in the presence or absence of 0.5 mM of nonradiolabeled COX-2 inhibitors rofecoxib, celecoxib, valdecoxib, etoricoxib, or CS-706 at 37°C for 2 h (n ϭ 3). In a separate study, the homogenate was incubated with 25 M [ 14 C]rofecoxib (only for humans), 100 M [ 14 C]rofecoxib, or 50 M [ 14 C]celecoxib at 37°C for 2 h (n ϭ 3). For evaluating the nonspecific binding, the same treatments were performed at 4°C for 2 h (n ϭ 3). After the incubation, the samples were washed and treated as described above, and the amount of net covalent binding was calculated. The LOX activity in the samples was also measured as described above.
Condensation Reaction of COX-2 Inhibitors with Benzaldehyde As a Model Reaction. The experiment to examine the reaction of COX-2 inhibitors with benzaldehyde was performed according to a previous report (Oitate et al., 2007) . In brief, 100 M of each compound (control; buffer only) was incubated with 1 mM benzaldehyde in potassium phosphate buffer (pH 7.4) at 37°C for up to 24 h. The reaction mixtures were frozen to stop the reaction and stored at Ϫ80°C until analysis using LC/MS.
Uptake and Efflux Experiments with HAOEC. Immediately before the uptake experiment, the culture medium was removed and the cells were washed three times with 1 ml of Hanks' balanced salt solution (HBSS; pH 7.4, 37°C; Invitrogen Corp., Carlsbad, CA). Uptake was initiated by adding 1 ml of endothelial cell medium containing 10 M [ 14 C]rofecoxib or [ 14 C]celecoxib (final concentration of dimethyl sulfoxide, 0.1%), and the cells were incubated at 37°C up to 360 min. After the incubation, the cells were washed three times with 1 ml of ice-cold HBSS to stop the uptake and to remove any extracellular 14 C-compounds. For the quantification of the compounds taken up, the cells were dissolved in 0.5 ml of HBSS containing Triton X-100 (final 0.1%) by sonication.
For the efflux experiment, each 14 C-compound (10 M) was incubated with the cells for 120 min at 37°C, and then the cells were washed in the same manner as described above. After that, the cells were incubated at 37°C with 1 ml of endothelial cell medium containing 20 M of each nonradiolabeled compound to start the efflux. At the designated time, the cells were washed and dissolved as described above.
Both the uptake and efflux experiments were done in triplicate. The cellular protein content was measured using a DC Protein Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA) in duplicate.
Radiodetection HPLC Analyses. After the incubation of [ 14 C]rofecoxib with aortic homogenates, the supernatants were analyzed by radiodetection HPLC as previously reported (Oitate et al., 2007) . The chromatographic system included a LC-10A system (Shimadzu Corp., Kyoto, Japan) equipped with an Xterra MS C18 column (4.6 ϫ 150 mm, 5 m; Waters Corp., Milford, MA) heated to 40°C. The mobile phase, consisting of distilled water containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B), was delivered at a flow rate of 1 ml/min, starting at 20% solvent B in solvent A and increasing the proportion of solvent B to 60% linearly for 20 min, and holding for 10 min at 60% solvent B. The effluent was monitored using a SPD-10A UV detector (280 nm; Shimadzu Corp.) and a Radiomatic 525TR radiochemical detector (PerkinElmer Life and Analytical Sciences, LC/MS Analyses. LC/MS was performed on a Waters Q-TOF Ultima mass spectrometer (Waters Corp.) operated in the positive and negative ion electrospray ionization modes for the analysis of the incubation mixture of each COX-2 inhibitor with benzaldehyde. The LC system used was a Waters Alliance 2695 separation module coupled with a 2996 photodiode array detector, scanned from 200 to 340 nm for 1 s. Chromatographic separations were carried out on an Xterra MS C18 column (2.1 ϫ 150 mm, 5 m; Waters Corp.) maintained at 30°C in a column oven. Solvent A (distilled water containing 0.1% formic acid) and solvent B (acetonitrile containing 0.1% formic acid) were delivered at a flow rate of 0.2 ml/min with the following linear gradient programs of solvent B (30 min): 30 to 90% for celecoxib and CS-706, 5 to 45% for etoricoxib, 20 to 80% for valdecoxib, and 10 to 70% for rofecoxib.
Radioactivity Measurements. Samples were solubilized with a tissue solubilizer NCS-II (1-2 ml; GE Healthcare Biosciences) under constant shaking at approximately 55°C. After solubilization, these samples were mixed with 10 ml of scintillator HIONIC-FLUOR (PerkinElmer Life and Analytical Sciences) and were subjected to radioactivity measurement by a liquid scintillation counter (model 2300TR; PerkinElmer Life and Analytical Sciences). The radioactivity value of each proteolytic fraction of the aorta was converted to a percentage of the total covalent-binding radioactivity, which is not extractable by washing with TCA and methanol. The radioactivity in the aorta was calculated as an equivalent (Eq) value of 14 C-compound and expressed as a concentration per gram of aorta. For the cell experiments, the intracellular concentrations were expressed as the amount per milligram of protein of cells (nmol/mg protein).
Data Analyses. Statistical analyses were performed by analysis of variance (ANOVA) followed by Dunnett's test using SAS System Release version 9.1 (SAS Institute Inc., Cary, NC). Differences were considered to be significant when p Ͻ 0.05.
Results
Acid, Organic Solvent, and Proteolytic Enzyme Treatments of Human Aorta. After incubation with [
14 C]rofecoxib, the human abdominal aortic homogenate was treated by successive extraction and washing with 0.6 M TCA, 80% methanol, and 100% methanol, and then the resultant precipitated fraction was enzymatically treated successively with collagenase, elastase, and pronase (n ϭ 1). As shown in Table 1 , the largest amount of the radioactivity from [ 14 C]rofecoxib was recovered in the elastolytic fraction (51.9% of the total covalent binding). The second largest amount of radioactivity was recovered in the collagenolytic fraction (40.6% of the total). The radioactivity recovered in the fraction after pronase treatment was 4.4%, and the radioactivity in the residue after the treatments with the proteolytic enzymes was 3.0%.
Effect of Protein Modifiers on in Vitro Covalent Binding of [ 14 C]Rofecoxib to Human Aorta Homogenate. Homogenate of human aorta, which had been pretreated with 10 mM of protein modifiers, was incubated with [ 14 C]rofecoxib (100 M) under a physiological pH condition (pH 7.4), and the amount of covalent binding to the proteins was measured (Fig. 3) . The radioactivity from [
14 C]rofecoxib bound covalently to the aorta without any protein modifiers was 1.10 Ϯ 0.06 g Eq/g (control). Pretreatment of the aortic homogenate with the protein modifiers BAPN, D-penicillamine, or hydralazine decreased the amount of covalent binding to 56, 52, and 31% of the control, respectively. Radiodetection HPLC analysis of the reaction mixture supernatant after the incubation demonstrated that the major component is the unchanged rofecoxib (Ͼ95%, data not shown). In a separate experiment, BAPN and hydralazine significantly decreased the LOX activity to 4.1 and 0% of the control, respectively, whereas rofecoxib did not decrease it at all. The LOX activity in the presence of D-penicillamine could not be measured because the fluorescence in the assay mixture was too strong, perhaps because of the production of some unknown compound(s) with fluorescence.
Effect of Several COX-2 Inhibitors on in Vitro Covalent Binding of [ 14 C]Rofecoxib to Rat and Human Aorta Homogenates. Homogenate of rat aorta was incubated with [
14 C]rofecoxib (50 M) under a physiological pH condition (pH 7.4) in the presence or absence of nonradiolabeled COX-2 inhibitors (0.5 mM), and the amount of the radioactivity that bound covalently to the proteins was measured ( Table 2 ). The covalently bound aortic radioactivity from [ 14 C]rofecoxib in the control was 1.66 Ϯ 0.07 g Eq/g. The amount was significantly decreased in the presence only of nonradiolabeled rofecoxib to 53% of the control, but not of the other COX-2 inhibitors at all. On the other hand, the binding amount of 50 M [ 14 C]celecoxib (0.19 Ϯ 0.17 g Eq/g) was significantly lower than that of [ 14 C]rofecoxib (control).
Human aortic homogenate was treated in the same way as described above, and the effect of nonlabeled COX-2 inhibitors (0.5 mM) on the covalent binding of [ 14 C]rofecoxib (50 M) was investigated (Table  2 ). In the control, the covalent binding of [ 14 C]rofecoxib was 0.46 Ϯ 0.02 g Eq/g. The addition of nonradiolabeled rofecoxib to the aortic homogenate significantly decreased it to 22% of the control, whereas the other COX-2 inhibitors had no such effect at all. tion mixtures was unchanged rofecoxib (Ͼ95%, data not shown). All the COX-2 inhibitors tested had no significant inhibitory effect on the LOX activity in rat and human aortas.
Condensation Reaction of COX-2 Inhibitors with Benzaldehyde As a Model Reaction. COX-2 inhibitors (100 M) were incubated with benzaldehyde (1 mM) in phosphate buffer under a physiological pH condition (pH 7.4), and the reaction mixtures were analyzed by LC/MS (Fig. 4) . In the case of rofecoxib, two peaks, P A and P B , which had been identified by LC/MS and LC-NMR analyses as the covalent adducts of rofecoxib with benzaldehyde and diastereomers, were detected as previously reported (Oitate et al., 2007) . On the other hand, in the cases of other COX-2 inhibitors, no reaction products which were considered to be adducts with benzaldehyde were detected at all in either the positive and negative ion analytical modes. No dehydrated form of each estimated adduct was observed in any of the compounds tested.
Uptake and Efflux of Radioactivity with HAOEC. In the incubation of 10 M [ 14 C]rofecoxib or [ 14 C]celecoxib with HAOEC, the uptake of radioactivity by the cells was observed (Fig. 5) . The radioactive concentration of [ 14 C]celecoxib at 120 min was about 3-fold higher than that of [ 14 C]rofecoxib (1.97 versus 0.64 nmol/mg protein). After an uptake of 120 min, the efflux of both compounds was very rapid, independent of their initial intracellular concentrations. In each case, the intracellular concentration was hardly detected at only 15 min after the start of efflux.
Discussion
After incubation with [
14 C]rofecoxib, human abdominal aortic homogenate was washed and extracted using TCA/methanol, and the residue was successively enzymatically treated with collagenase, elastase, and pronase and then the radioactivity recovered in each fraction was measured. As shown in Table 1 , the largest amount of the radioactivity from [ 14 C]rofecoxib that was covalently bound to the aorta was recovered in the elastolytic fraction, suggesting that rofecoxib is covalently bound to elastin in the human aorta. This result was consistent with that obtained in rat aorta (Oitate et al., 2006) .
To investigate the reactivity of rofecoxib with the allysine aldehyde in human elastin compared with that in rat elastin (Oitate et al., 2007) , in vitro binding studies using human aortic homogenate were conducted in the presence of some protein modifiers (Fig. 3) . Pretreatment of BAPN, a specific inhibitor of LOX (Tang et al., 1983) , significantly decreased the covalent binding of [ 14 C]rofecoxib, probably via the prevention of allysine production from lysine. The covalent binding of [ 14 C]rofecoxib was also significantly decreased by pretreatment with D-penicillamine and hydralazine, which have been reported to react with protein aldehydes in connective tissues and to form thiazolidine or hydrazone analog (hydralazine can also inhibit LOX activity) Deshmukh and Nimni, 1969; Gallop and Paz, 1975; Numata et al., 1981; Howard-Lock et al., 1986) . These results strongly suggested that the aldehydic functional 
C͔Rofecoxib (50 M) was incubated with aortic homogenate ͓5% (w/v)͔ in the presence or absence of each of the COX-2 inhibitors (0.5 mM) at 37°C for 2 h. In a separate study, the homogenate was incubated with 25 M ͓ 14 C͔rofecoxib (only for humans), 100 M ͓ 14 C͔rofecoxib, or 50 M ͓ 14 C͔celecoxib at 37°C for 2 h (n ϭ 3). The amount of covalent binding was measured as described under Materials and Methods. group in human elastin, i.e., the aldehyde group of allysine, is relevant to the covalent binding with rofecoxib, as it is in rat elastin (Oitate et al., 2007) . In addition, the covalent binding of [ 14 C]rofecoxib to human aorta was concentration-proportional in the range between 25 to 100 M ( Table 2 ), suggesting that the binding capacity is fairly high.
In the enzymatic fractionation of the human aorta (Table 1) , the rank order of recovery of radioactivity was similar to that in rat aortas after oral administration of [
14 C]rofecoxib in vivo (Oitate et al., 2006) . However, it differed in one way: in the rat aorta almost all of the radioactivity (Ͼ90%) was recovered in the elastolytic fraction with a small percentage in the collagenolytic fraction, whereas in the human aorta approximately 41% of the total binding radioactivity was recovered in the collagenolytic fraction as well as in the elastolytic fraction. This difference might come from dissimilarities in the parts of the aortas used (human, abdominal; rat, thoracic) . It has been reported that the content of elastin in the aortic wall decreases progressively, whereas in contrast, the content of collagen increases, since the aorta is traversed longitudinally from the arch to abdominal (Grant, 1967) . In collagen, allysine is also formed from the lysine residue by LOX and contributes importantly to the elasticity of CV tissues, as well as elastin (Eyre et al., 1984) . have reported that, in the case of elastin, 5 to 16 lysyl residues per 10 3 amino acids are converted to allysine residues, compared with one lysyl residue per 10 3 amino acids in collagen. From the above results in the human abdominal aorta, it was suggested that rofecoxib is capable of covalently binding to the allysine aldehyde in elastin and partially binding to that in collagen.
After the incubation of [ 14 C]rofecoxib with rat aortic homogenate in vitro in the presence or absence of nonradiolabeled rofecoxib, celecoxib, valdecoxib, etoricoxib, and CS-706, the amount of covalent binding was measured ( Table 2 ). The binding of [ 14 C]celecoxib was significantly lower than that of [ 14 C]rofecoxib, supporting our previous result; that is, there was no retention of radioactivity in the aorta after oral administration of [ 14 C]celecoxib to rats in vivo, whereas the radioactivity from [ 14 C]rofecoxib was retained by and accumulated in the rat aorta (Oitate et al., 2006) . The covalent binding of [ 14 C]rofecoxib to rat aortic homogenate in vitro was significantly decreased by the addition of only rofecoxib, whereas the other COX-2 inhibitors had no such effect. As well as the above results in rats, only the addition of nonradiolabeled rofecoxib to human aortic homogenate could significantly reduce the covalent binding of [ 14 C]rofecoxib, and the binding of [ 14 C]celecoxib was much less than that of [ 14 C]rofecoxib (Table 2 ). In the cases of both rats and humans, rofecoxib did not affect the LOX activity at all. Therefore, the decrease of [ 14 C]rofecoxib binding by nonradiolabeled rofecoxib was thought to be due to a competitive inhibition of allysine aldehyde. This suggested that other COX-2 inhibitors except for rofecoxib have no reactivity with the allysine aldehyde in human elastin, the same as in rats and collagen.
To estimate the reactivity of COX-2 inhibitors with the allysine aldehyde in human elastin and collagen with certainty, they were incubated with benzaldehyde, a model compound of allysine, under a physiological pH condition, as previously reported (Oitate et al., 2007) . In the case of rofecoxib (as a positive control), the two peaks P A and P B were detected as reported previously (Fig. 4) . By LC/MS and LC-NMR analyses, they had been identified as the covalent adducts of rofecoxib with benzaldehyde and diastereomers (Oitate et al., 2007) . On the other hand, in the cases of other COX-2 inhibitors, no reaction products that were considered to be adducts with benzaldehyde were detected at all by LC/MS analyses operated in both the positive and negative ion modes. The C5 position in rofecoxib was considered to be sufficiently nucleophilic to react with aldehyde (Oitate et al., 2007) . The other COX-2 inhibitors tested structurally do not contain a carbon atom carrying hydrogen ␣ or allylic to the carbonyl group (Fig. 2) , and therefore it is reasonable to conclude that these compounds did not react with benzaldehyde.
In clinical situations, the C max of rofecoxib at a general therapeutic dose (25 mg) was reported to be ϳ1 M (Davies et al., 2003) . On the other hand, the in vitro binding of [ 14 C]rofecoxib to the human aorta was linear, at least in the concentration range of 25 to 100 M (Table  2) , and the binding capacity was high, as mentioned above. Considering that rofecoxib binds to allysine in a covalent manner, rofecoxib has often been chronically dosed in clinical situations, and because both elastin and collagen have very slow turnover rates (Maroudas et al., 1992; Petersen et al., 2002) , rofecoxib would be increasingly accumulated in the human aorta depending on the dose frequency. From the above results, it is presumed that in clinical situations rofecoxib, but not other COX-2 inhibitors, might prevent the crosslinking process of elastin and collagen, leading to the degradation of elastin and collagen, the dysfunction of arteries, and finally CV events.
It has been generally accepted that CV events caused by selective COX-2 inhibitors might be partially due to an imbalance of the concentration ratio of two prostanoids with major CV actions: PGI 2 , a vasodilator and inhibitor of platelet aggregation, and TxA 2 , a vasoconstrictor and promoter of platelet aggregation. That is, selective COX-2 inhibitors diminish the production of PGI 2 in the endothelium, but not TxA 2 in the platelets, so that the relative concentration of TxA 2 increases around the affected area, which might increase the CV risks (McAdam et al., 1999 (Fig. 5) . On the other hand, the efflux of both compounds was very rapid without any retention of radioactivity in the cells, suggesting that both compounds might not be retained by and accumulated in human aortic endothelial cells in vivo. When the concentrations in the plasma are high immediately after the administrations, it is thought that the concentrations in the endothelial cells and platelets are also high and that all selective COX-2 inhibitors, including rofecoxib and celecoxib, would theoretically cause a PGI 2 / TxA 2 imbalance. However, it is quite difficult to postulate that rofecoxib has an especially strong effect in causing an imbalance compared with other compounds.
In conclusion, it was suggested that rofecoxib, but not the other COX-2 inhibitors, can covalently bind to the allysine aldehyde in human elastin as well as that in rats (Fig. 1B) and that it can bind partially in human collagen. This would lead to the prevention of the normal cross-linking processes and dysfunction of the arteries. This might be one of the main causes of CV events by rofecoxib in clinical situations. In this view, other COX-2 inhibitors could be less toxic in terms of CV risks than rofecoxib.
